Status:

COMPLETED

Value of Urodynamic Evaluation

Lead Sponsor:

Carelon Research

Collaborating Sponsors:

University of Alabama at Birmingham

University of California, San Diego

Conditions:

Urinary Incontinence

Eligibility:

FEMALE

21+ years

Phase:

PHASE4

Brief Summary

Although no reliable and specific figures are available for the total expenditure on UDS, UDS is commonly performed for patients with urinary incontinence (UI) regardless of gender and age. UDS is typ...

Eligibility Criteria

Inclusion

  • Female
  • Predominant SUI as evidenced by all of the following:
  • Self-reported stress-type UI symptoms, of duration \>3 months\*
  • MESA stress symptom score (percent of total possible stress score) greater than MESA urge symptom score (percent of total possible urge score)
  • Observation of leakage by provocative stress test at any volume
  • Eligible for randomization to either treatment group
  • Eligible for SUI surgery
  • Desires non-conservative therapy for SUI
  • PVR \<150ml by any method. (May repeat once if initial measure is abnormal)
  • Negative urine dipstick (negative result = trace or less for leukocytes \& nitrites) or negative UA or negative culture
  • Available to initiate SUI treatment within 6 weeks of randomization
  • Available for 12-months of follow-up and able to complete study assessments, per clinician judgment.
  • Signed consent form.
  • Patient can be rescreened after respective time interval has been met.

Exclusion

  • Age \<21 years\*
  • Currently undergoing or has had recommended treatment of apical or anterior prolapse
  • No anterior or apical prolapse \> +1 on standing straining prolapse exam
  • Pregnant or has not completed child bearing.
  • \<12 months post-partum\*†
  • Active malignancy of cervix, uterus, fallopian tube(s) or ovary \> Stage I, or bladder of any Stage
  • History of pelvic radiation therapy
  • Previous incontinence surgery
  • Current catheter use
  • Neurological disease known to affect bladder storage (e.g. MS, Parkinsonism, CVA)
  • Previous (i.e. repaired) or current urethral diverticulum
  • Prior augmentation cystoplasty or artificial sphincter
  • Implanted nerve stimulators for urinary symptoms or previous botox bladder injections.
  • Any pelvic surgery within the last 3 months\*
  • Previous placement of synthetic mesh on a vaginal approach in the anterior compartment
  • Participation in another treatment intervention trial that might influence results of this trial.
  • A urodynamic result reviewed by the investigator in the preceding 12 months or any recollection by the investigator of urodynamic results on that subject.
  • Patient can be rescreened after respective time interval has been met.
  • "Partum" is defined as a delivery or other termination that occurs after 20 weeks gestation.

Key Trial Info

Start Date :

November 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2010

Estimated Enrollment :

630 Patients enrolled

Trial Details

Trial ID

NCT00803959

Start Date

November 1 2008

End Date

June 1 2010

Last Update

August 6 2013

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

University of Alabama

Birmingham, Alabama, United States, 35294

2

University of California

San Diego, California, United States, 92103

3

Loyola University Medical Center

Maywood, Illinois, United States, 60153

4

University of Maryland

Baltimore, Maryland, United States, 21201